Person:
Montesino San Martín, Manuel

Profile Picture

Email Address

Birth Date

Research Projects

Organizational Units

Job Title

Last Name

Montesino San Martín

First Name

Manuel

person.page.departamento

ORCID

0000-0002-0822-600X

person.page.upna

811682

Name

Filters

20231
Reset filters

Settings

Author: Sánchez Iriso, Eduardo × Subject: Cost-effectiveness ×

Search Results

Now showing 1 - 1 of 1
  • Thumbnail Image
    PublicationOpen Access
    Cost-utility analysis of prostatic artery embolization for treatment of lower urinary tract symptoms
    (2023) Capdevila, Ferran; Insausti, Íñigo; San Miguel Elcano, Ramón; Sánchez Iriso, Eduardo; Montesino San Martín, Manuel; Ciencias de la Salud; Osasun Zientziak; Economía; Ekonomia
    Purpose: To perform a post hoc cost–utility analysis of a randomized controlled clinical trial comparing prostatic artery embolization (PAE) and transurethral resection of the prostate (TURP) in patients with lower urinary tract symptoms secondary to benign prostatic hyperplasia. Materials and Methods: We conducted a cost–utility analysis over a 5-year period to compare PAE versus TURP from a Spanish National Health System perspective. Data were collected from a randomized clinical trial performed at a single institution. Effectiveness was measured as quality-adjusted life years (QALYs), and an incremental cost-effectiveness ratio (ICER) was derived from the cost and QALY values associated with these treatments. Further sensitivity analysis was performed to account for the impact of reintervention on the cost-effectiveness of both procedures. Results: At the 1-year follow-up, PAE resulted in mean cost per patient of €2904.68 and outcome of 0.975 QALYs per treatment. In comparison, TURP had cost €3846.72 per patient and its outcome was 0.953 QALYs per treatment. At 5 years, the cost for PAE and TURP were €4117.13 and €4297.58, and the mean QALY outcome was 4.572 and 4.487, respectively. Analysis revealed an ICER of €2121.15 saved per QALY gained when comparing PAE to TURP at long-term follow-up. Reintervention rate for PAE and TURP was 12% and 0%, respectively. Conclusions: Compared to TURP, in short term, PAE could be considered a cost-effective strategy within the Spanish healthcare system for patients with lower urinary tract symptoms secondary to benign prostatic hyperplasia. However, in long term, the superiority is less apparent due to higher reintervention rates.